2017 Fiscal Year Final Research Report
Development of novel anti-cancer immune therapies targeting CD147 antigen
| Project/Area Number |
15K10590
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
黄 鵬 岡山大学, 医歯薬学総合研究科, 助教 (00610841)
渡部 昌実 岡山大学, 大学病院, 教授 (70444677)
植木 英雄 岡山大学, 医学部, 技術専門職員 (90537218)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 癌治療 / ＣＤ147 / 腫瘍学 |
|---|
| Outline of Final Research Achievements |
In this study, we validated and confirmed the anti-cancer immune activity of the fusion proteins consisted of CD147 antigen and cytokines, in in vivo experimental models. We also disclosed the inhibitory function of REIC/Dkk-3 protein overexpressed by Ad-REIC agents, in the endogenous CD147 expression in bladder and prostate cancer cells. We believe that the CD147 antigen could be a promising target for anti-cancer therapy. We are going to conduct the further study to develop novel anti-cancer immune therapies targeting CD147 antigen.
|
| Free Research Field |
腫瘍学
|
